Introduction
Angiogenesis is the generation of new blood vessels from an existing vascular bed. The process is quiescent in vascular endothelium of healthy tissue due to a limited turnover of the endothelial cells of more than 1000 days. The endothelial cells however can divide with a turnover of five days during wound healing in order to develop new blood vessels [1] . When blood vessels grow uncontrollably, angiogenesis promotes the progression of a variety of disorders: proliferative retinopathies, agerelated macular degeneration, tumors, rheumatoid arthritis, psoriasis, etc. Angiogenesis is a process involving extensive interaction between compounds of different biological matrices. The switch to angiogenesis involves a change in the local equilibrium between positive and negative regulators of microvessels. Several angiogenic and anti-angiogenic factors have been described [2] .
Since the description of vascular endothelial permeability factor (VPF) [3] , vascular endothelial growth factor (VEGF) [4] and vasculotropin [5] , the role played by these identical molecules (VPF, VEGF, vasculotropin) in the regulation of angiogenesis has been studied in a great number of laboratories over the last few years. VEGF is a homodimeric ±45 kDa glycoprotein with potent angiogenic, mitogenic and vascular permeability enhancing activities specific for endothelial cells [6] . The VEGF mRNA undergoes alternative splicing which results in four homodimeric isoforms: VEGF )2 i, VEGF165, VEGFi 89 and VEGF 2 o6-The two shorter isoforms display both mitogenic and permeability enhancing activity, whereas the two longer isoforms only have vascular permeability enhancing activity. VEGFi 89 and VEGF 2 o6 are highly basic, heparin binding proteins that are tightly bound to the extracellular matrix. VEGF 12 i is a non-heparin binding acidic protein and is freely diffusible. VEGF 165 has intermediate properties, is less strongly bound to the extracellular matrix and may exist in equilibrium with a soluble form [7] .
VEGF is synthesized and secreted by a variety of cultured tumor cells [8] , as well as by human solid tumors such as brain tumors [9] [10] [11] , lung cancers [12, 13] , breast carcinomas [14] , gastrointestinal tract adenocarcinomas [15] , renal and bladder carcinomas [15, 16] and epithelial ovarian carcinomas [17] [18] [19] . Serum VEGF levels in cancer patients have been shown to be significantly higher than those from apparently healthy individuals [20] [21] [22] [23] . As a result, the determination of VEGF levels in serum was reported as a possible tumor marker in several types of human malignancies, such as breast cancer [24, 25] , colorectal cancer [26, 27] , epithelial ovarian neoplasms [28, 29] , hepatocellular carcinoma [30] , non-Hodgkin's lymphoma [31] , renal eel carcinoma [32] and sarcomas [33] . Elevated serum VEGF levels have also been reported in various liver diseases [34] , pregnancy and preeclampsia [35, 36] and inflammatory bowel diseases [37] . Recently, Banks et al. [38] demonstrated that VEGF released by activated platelets contributed significantly to VEGF levels measured in the serum of healthy volunteers. These results confirmed the earlier findings of Mohle et al. [39] who showed that ex vivo generated megakaryocytes and platelets release VEGF upon stimulation with thrombin. Verheul et al. [40] also provided evidence for VEGF transport by platelets, indicating that serum VEGF mainly reflects platelet counts rather than tumor burden in cancer patients.
In this study, we further elaborated recently published data [41] where we compared VEGF levels in different blood compartments in cancer patients and healthy volunteers in order to assess the most suitable way of blood processing for measuring VEGF as a marker of tumor related angiogenesis.
Patients and methods

Volunteers and patients
In the first setting, we collected randomly blood samples from 22 apparently healthy volunteers, personnel of the Gasthuisberg University Hospital, Leuven. Eight of these individuals were women, sixteen were men, and their age ranged from 21-61. We also randomly collected blood samples from 18 patients with histologically proven malignancies. All patients were hospitalized for further investigation of clinically diagnosed disease progression or entered the hospital to start a new course of chemotherapy (proven disease progression and at least four weeks without systemic treatment, Table 1 ). For the second setting of experiments, blood samples were analyzed in a smaller group of 11 similar patients and 10 volunteers (Table 2 ). Finally, we collected samples in 18 patients with similar characteristics (data not shown) of the previous groups. Informed consent as prescribed by the local ethical committee was obtained.
Sample collection
Blood samples were collected in sterile tubes (Becton Dickinson Vacutainer Systems Europe, France). All samples were taken between 8.00 and 8.45 AM, without overnight fasting. From volunteers and most patients, blood samples were taken peripherally using a constricting tourniquet. In patients with a port-a-cath, this system was used to access the venous bloodstream.
In the first setting, a 10 ml serum tube, a 10 ml EDTA K3-plasma tube and two 4.5 ml Sodium-Citrate 0.129 M Silic. (1/10) plasma tubes were taken sequentially. The same procedure was used in volunteers and patients. In order to generate serum, blood was allowed to coagulate for at least 30 min at room temperature and centrifuged at 3000 x g for 10 min at 20 C. EDTA-blood was centrifuged within 15 Male  Male  Male  Male  Male  Female  Female  Female  Female  Female  Male  Male  Male  Female  Female  Male  Female  Female  Male  Male  Male  Male min of collection at 3000 x g for 10 min at 20 °C. The citrated blood was centrifuged at 180 x g for 10 min at 20 °C to generate platelet-rich plasma (PRP). After removal of the supernatant (PRP), the sample was again centrifuged at 3000 x g for 10 min at 20 °C to obtain platelet-poor plasma (PPP). After subjecting PRP to a platelet count, it was treated with HORM collagen 1 mg/ml (Nycomed GmbH, Germany) and incubated for 10 min at 37 °C and constantly stirred to obtain maximal platelet activation, secretion and aggregation. After centrifugation for 12 min at 2600 x g at 20 °C, the aggregated platelet sediment was discarded.
In the second setting, we took only a serum tube and a CTADplasma tube. CTAD tubes (Becton Dickinson Vacutainer Systems Europe, France) contain four anticoagulants (sodium citrate, theophylin, adenosine, dipyridamole) to obtain maximal platelet stabilization. After blood sampling, CTAD-tubes were immediately put on ice for a maximum of 15 min and centrifuged at 2500 x g for 30 min at 4°C. The serum was generated as described earlier.
In the third group of 18 patients, we only sampled a 4.5 ml SodiumCitrate tube, that was processed within one hour of venepuncture and centrifuged at 2000 x g for 10 min at 20 °C as was recommended by Banks et al. [38] and a 4.5 ml CTAD tube, processed as described above.
All fractions were stored in aliquots at -20 °C. After thawing, each aliquot was assayed only once.
Enzyme immunoassay VEGF concentrations were determined using the Quantikine Human VEGF enzyme-linked immunosorbent assay (ELISA) (R&D Systems Inc., Minneapolis, MN), a 4.5 hour solid phase ELISA designed to measure VEGF| 6 5 levels in cell culture supernatants, serum and plasma. This ELISA is designed to measure VEGFi 65 . but due to cross reactivity it also measures VEGF ]2 |. Optical densities were measured with a Bio-Tek automated microplate reader EL311 at 450 nm, with correction at 570 nm. The blank was subtracted from the duplicate readings of each standard and sample. A standard curve, performed for each microplate, was created by plotting the log of the mean cancer patients (P). A significant difference in VEGFs levels between volunteers and cancer patients was observed, whereas VEGF levels in PRP and in platelets were not statistically significant.
absorbance for each standard on the Y-axis against the log of the standard concentration on the X-axis (range 15.6-2000 pg/ml) and the line of best fit was determined by regression analysis. Concentrations are reported in pg/ml. Inter-and intra-assay variation was found to conform to the product information from R & D Systems Inc. According to the manufacturer, the minimum detectable dose was typically less than 9 pg/ml. Values below 9 pg/ml were equalized to zero. To assess the possible activation of platelets in different plasma samples, we measured platelet factor 4 (PF4) by an ELISA-method, Asserachrom PF4. PF4 plasma levels in the normal adult population are in the range of 0-5 IU/ml (Diagnostica Stago, Asnieres-sur-Seine, France).
VEGF levels measured in PRP, PPP, EDTA-plasma, citrated-plasma, CTAD-plasma and serum are denoted as VEGF PRP , VEGFp PP , VEGF E D T A , VEGFc, V E G F C T A D and VEGF S , respectively. Since VEGFp R p encompasses VEGF PPP as well as platelet released VEGF, we calculated platelet released VEGF by subtracting VEGFppp from V E G F P R P ( V E G F P R P -VEGFpPP = VEGFp]t).
Statistical analysis
Data were analyzed using a computer-supported statistical program (Statview for Macintosh). VEGF and PF4 distributions in volunteers and cancer patients were compared using the Mann-Whitney U-test (unpaired, non normally distributed groups). When VEGF distribution among different blood fractions was compared, we used the Wilcoxon matched pairs test (paired, non normally distributed groups).
In Figure 1 and Figures 3-6 , the distribution of the data is represented by boxplot configuration. The horizontal line in the middle of the rectangle (P 75 and P25) represents the median (P50). The P95 and 
Results
In the first setting, we observed in agreement with previous reports [20] [21] [22] [23] , a significant difference in VEGF S levels between volunteers and cancer patients (P = 0.0027, Figure 1 ). However, some volunteers displayed VEGF S levels that were situated above the median VEGF S concentration typical for the cancer patient population. While measuring VEGF levels in the corresponding plasma fractions (EDTA, PPP, PRP), the following observations were made. A broader range and discrete trend towards higher VEGF PRP and VEGF p i t levels in the cancer group was seen as compared to volunteers (Figure 1 ). However the difference between both populations was not statistically significant (VEGF PRP : P = 0.208; VEGF pU : P = 0.187).
A significant correlation between VEGF S and VEGF P ] t levels in volunteers was found (r = 0.76, P = 0.00004, Figure 2a) . Analysis of the correlation between VEGF S and VEGFpi t in cancer patients showed a similar correlation in a comparable VEGF concentration range as in the volunteers (r = 0.60, P = 0.023, Figure 2b ). Above this range we observed a horizontal-like plateau, suggesting a surplus of VEGF not originating from plateletrelease. The theoretical VEGF production per platelet was calculated by dividing VEGF pU (pg/ml) by the platelet count (x 10 6 /ml). The platelet counts did not differ statistically between volunteers and cancer patients (P = 0.237, Table 3 ). The mean VEGF production per 10 6 platelets in volunteers was 0.30 pg/platelet x 10 6 (STDEV = 0.18) and differed significantly (P = 0.0149) from the mean VEGF production per 10 6 platelets in cancer patients (mean 0.56 pg/platelet x 10 6 , STDEV = 0.38; Figure 3 ). When studying V E G F E D T A and VEGF PPP , significantly higher levels were observed in cancer patients (VEGF EDTA : P = 0.003; VEGF PPP : P = 0.0007) than in volunteers ( Figure 4 ). As shown in Figure 4 , we observed a clear separation between VEGF PPP levels between both groups.
Platelet factor 4 was measured in PPP to assess the degree of total platelet activation, systemic activation or activation induced by the blood collection procedure. No significant difference in PF4 levels between both groups was found {P -0.9612, Table 3 ).
The distribution of the age of the patient group differ significantly from the volunteers. No correlation between age en VEGF S , VEGF EDTA , VEGF PPP , VEGF PRP and VEGF P u was found (data not shown).
As a control, we investigated the possible binding of VEGF to the anticoagulants and collagen. The standard dilution series as prescribed by R&D Systems were compared to three standard dilution series after the addition of sodium citrate 0.129 M (1/10), EDTA-K3 or collagen 10 pg/ml, respectively. The parameters of the linear equations did not differ at a 95% significance level (data not shown).
To investigate the best way of processing blood, carefully avoiding platelet activation, we compared in the second setting VEGF levels measured in CTAD-plasma versus serum in a smaller group of 10 patients and 9 volunteers. VEGF S levels ranged from 75-609 pg/ml (median 151 pg/ml) in volunteers, from 49-1260 pg/ml (median 169 pg/ml) in cancer patients. There was no statistically significant difference between both popula- tions (P = 0.08237). However, as is shown in Figure 5 , significantly different VEGF levels were observed in CTAD-plasma between these two groups (P -0.0109). PF4 levels measured in CTAD-plasma were in the normal range and did not differ between the two groups (P = 0.6221).
In the last group of 18 patients, we compared the method described by Banks et al. [38] to the CTADplasma as elaborated in the second setting. As is shown in Figure 6 a statistically significant difference (P -0.00019) in VEGF plasma concentration between both methods is present. When analyzing PF4 plasma concentrations in these samples, a statistically higher concentration is detected in the citrated plasma (median 71.0 IU/ml; IQR 21.4 IU/ml) versus the CTAD plasma (median 27.5 IU/ml, IQR 27.5 IU/ml, P = 0.00023).
Discussion
We have confirmed that cancer patients display significantly higher VEGF S levels than healthy individuals [20] [21] [22] [23] . In the literature, elevated VEGF S levels are reported in cancer patients as a possible tumor marker or 'predictive factor' in certain malignancies [24, [26] [27] [28] [29] [30] [31] [32] [33] . As VEGF is known to be secreted by tumor cells of different origin in vitro, it is suggested that VEGF is also produced and released by human tumors [23] . The higher VEGFs levels detected in cancer patients compared to healthy individuals, and the detection of the highest VEGF S levels in patients with metastases are supposed to be a direct consequence of VEGF production by tumor [23] . Tumor infiltrating inflammatory cells and circulating peripheral white blood cells may also contribute to the VEGF S concentration as these cells have been shown to express VEGF [42, 43] . Recently, it has been demonstrated that VEGF is also released by activated platelets in healthy volunteers [38] and cancer patients [40] . Further investigation on the expression of VEGF in peripheral blood showed detectable VEGF mRNA in different peripheral blood cell fractions, including platelets [44] . As a consequence, the suitability of serum for the determination of VEGF levels can be questioned.
To investigate the most suitable way of processing blood and measuring VEGF for use as a possible marker of tumor related angiogenesis, we analyzed VEGF concentrations in different blood compartments in cancer patients and healthy volunteers.
We explored the origin of VEGF S by inducing a maximal artificial platelet activation, secretion and aggregation in PRP from both populations, volunteers and cancer patients. No significant difference in VEGF PRP and VEGFpi, levels between cancer patients and volunteers was observed, although there was a trend towards higher values in the cancer patients. If it is assumed that VEGF S was only derived from platelets, VEGF PRP should display the same distribution as seen for VEGF S . As this is not so suggests either only a submaximal induction of platelet activation, secretion and aggregation in vitro when generating serum, which is unlikely, or the existence of another important fraction that could influence the serum level. The higher, although not significantly higher VEGF p | t levels in cancer patients in comparison with the volunteers were a consequence of a higher VEGF release per platelet, rather as a consequence of the total platelet count which was not significantly different between the two groups.
This data confirm the existence of a physiological store of VEGF in platelets or platelet adherent VEGF that can be released when platelet activation, aggregation and secretion is induced by collagen. As recently suggested by Wartiovaara et al. [44] , VEGF is residing in the a-granules of platelets. We observed that cancer patients delivered approximately twice as much VEGF per platelet than volunteers. Both mechanisms, a higher 'physiological' storage induced by impaired megakaryogenesis or de novo synthesis in the platelets, or endocytosis/adhesion of more abundant circulating VEGF to platelets, could be responsible for this increased concentration in cancer patients. When platelets are activated in vivo, as in several disease processes, and thus release VEGF or when VEGF is abundantly secreted by tumoral tissue, excess VEGF could become measurable in plasma when the endocytosis/adhesion capacity of the platelets is saturated.
In order to assess free circulating VEGF, VEGF concentrations were measured in EDTA plasma and PPP in the first setting. Cancer patients displayed significantly higher VEGF EDTA and VEGF PPP levels than the volunteers. When comparing the distribution of theVEGF EDTA levels and the VEGF PPP levels, the best discrimination between volunteers and cancer patients was observed in PPP. Although EDTA is known to influence platelet shape by changing Ca 2+ concentrations, no statistically significant difference (P = 0.088279) in this populations have been observed in VEGF EDTA versus VEGF PPP .
The concentration of PF4 in PPP did not differ significantly between the volunteers and the cancer patients, indicating that there was no difference in platelet activation and thus platelet-derived VEGF could not be responsible for the measured differences of VEGF PPP in cancer patients and volunteers.
To investigate the best way of processing blood, carefully avoiding platelet activation, we measured VEGF levels in serum and CTAD-plasma as a second series of experiments. In this rather small test population, statistically different VEGF CTAD levels were detected (P = 0.0109) comparing volunteers and cancer patients. As PF4 levels measured in CTAD-plasma were in the normal range and did not differ between the two groups (P -0.6221), these results confirmed our initial experimental results and allow us to discriminate cancer patients from volunteers by measuring free circulating VEGF, not originating from platelet activation. When comparing the method described by Banks et al. [38] to the CTAD-plasma in the third patient group, significantly higher VEGF concentrations are detected in the citrated plasma versus the CTAD-plasma. As the PF4 concentrations are also significantly elevated in the citrated plasma, the observed difference in VEGF concentrations is likely to be caused by the platelet activation in vitro during sample treatment.
The exact origin of free circulating VEGF remains uncertain at this moment. Preliminary measurements in a rat tumor model suggest that an excess of free circulating VEGF is originating from early neoangiogenesis. In our measurements, the white blood cell fraction was not investigated although subfractions have been shown to express VEGF [42] [43] [44] . The role of the red blood cell fraction is currently under investigation, using a new technique (MESED®) which enables intrinsic quantitative analysis of substances in/at the erythrocyte [45] . In order to analyze possible differences in VEGF isoforms delivered by platelets versus free circulating VEGF, further analysis is ongoing.
Currently, several antiangiogenic drugs have been approved for use in cancer patients and clinical trials are evaluating, in primary or secondary objectives, their evidence of antitumor activity by clinical or biological parameters. As previously independently described by several authors [24, [26] [27] [28] [29] [30] [31] [32] [33] the determination of VEGF S has proven to be useful as a tumor marker with a potential role as predictive factor for disease progression. We assessed VEGFg as a possible predictive factor in patients with solid tumors treated with PNU-145156E in a phase I trial [46] . VEGFg levels did not change, no tumor responses have yet been observed.
As we now have more insights in the origin of VEGF S , we are assessing VEGF S and plasma VEGF levels in several clinical trials, especially in phase I studies of anti-angiogenic drugs. We therefore highly recommend a correct use of the CTAD tube in order to avoid in vitro platelet activation to assess in vivo free circulating VEGF.
